245 related articles for article (PubMed ID: 17041286)
41. Assessment of medication adherence in patients with schizophrenia: the Achilles heel of adherence research.
Kikkert MJ; Barbui C; Koeter MW; David AS; Leese M; Tansella M; Gieler A; Puschner B; Schene AH
J Nerv Ment Dis; 2008 Apr; 196(4):274-81. PubMed ID: 18414121
[TBL] [Abstract][Full Text] [Related]
42. Survey of medication adherence in patients with schizophrenia--Korean ADHES data.
Kim SW; Yoon JS; Choi SK
Hum Psychopharmacol; 2006 Dec; 21(8):533-7. PubMed ID: 17133616
[TBL] [Abstract][Full Text] [Related]
43. Fewer symptoms vs. more side-effects in schizophrenia? Opposing pathways between antipsychotic medication compliance and quality of life.
Staring AB; Mulder CL; Duivenvoorden HJ; De Haan L; Van der Gaag M
Schizophr Res; 2009 Aug; 113(1):27-33. PubMed ID: 19525092
[TBL] [Abstract][Full Text] [Related]
44. [Attitude of family to neuroleptics].
Angermeyer MC; Matschinger H
Psychiatr Prax; 1999 Jul; 26(4):171-4. PubMed ID: 10457968
[TBL] [Abstract][Full Text] [Related]
45. [Therapeutic treatment with neuroleptics. I: State of research on mechanisms of action, effectiveness and compliance in treatment of psychoses].
Krausz M; Sorgenfrei T
Psychiatr Prax; 1991 Jan; 18(1):9-13. PubMed ID: 1674156
[TBL] [Abstract][Full Text] [Related]
46. The relationship between patient satisfaction and treatment outcomes in schizophrenia.
Chue P
J Psychopharmacol; 2006 Nov; 20(6 Suppl):38-56. PubMed ID: 17046986
[TBL] [Abstract][Full Text] [Related]
47. Cost-utility analysis in schizophrenia.
Awad AG; Voruganti LP
J Clin Psychiatry; 1999; 60 Suppl 3():22-6; discussion 27-8. PubMed ID: 10073373
[TBL] [Abstract][Full Text] [Related]
48. Startle gating deficits in a large cohort of patients with schizophrenia: relationship to medications, symptoms, neurocognition, and level of function.
Swerdlow NR; Light GA; Cadenhead KS; Sprock J; Hsieh MH; Braff DL
Arch Gen Psychiatry; 2006 Dec; 63(12):1325-35. PubMed ID: 17146007
[TBL] [Abstract][Full Text] [Related]
49. Drug attitude and other predictors of medication adherence in schizophrenia: 12 months of electronic monitoring (MEMS(®)) in the Swedish COAST-study.
Brain C; Allerby K; Sameby B; Quinlan P; Joas E; Karilampi U; Lindström E; Eberhard J; Burns T; Waern M
Eur Neuropsychopharmacol; 2013 Dec; 23(12):1754-62. PubMed ID: 24091164
[TBL] [Abstract][Full Text] [Related]
50. The impact of novel antipsychotic drugs on quality of life among people suffering from schizophrenia.
Jukić V; Barić V; Culav-Sumić J; Herceg M; Majdancić Z; Werft-Cop M
Coll Antropol; 2003; 27 Suppl 1():119-24. PubMed ID: 12955901
[TBL] [Abstract][Full Text] [Related]
51. Health-related quality of life of Chinese people with schizophrenia in Hong Kong and Taipei: a cross-sectional analysis.
Chan SW; Hsiung PC; Thompson DR; Chen SC; Hwu HG
Res Nurs Health; 2007 Jun; 30(3):261-9. PubMed ID: 17514721
[TBL] [Abstract][Full Text] [Related]
52. [Recovery and remission in schizophrenia. Results from a naturalistic 2-year follow-up inpatient study].
Wolter A; Preuss U; Krischke N; Wong JW; Langosch JM; Zimmermann J
Fortschr Neurol Psychiatr; 2010 Aug; 78(8):468-74. PubMed ID: 20694939
[TBL] [Abstract][Full Text] [Related]
53. [Quality of life and therapeutic result in outpatients with schizophrenia under flupenthixol treatment].
Kühn KU; Quednow BB; Landen H; Riedel M; Thiel M
Fortschr Neurol Psychiatr; 2004 Jul; 72(7):397-403. PubMed ID: 15252753
[TBL] [Abstract][Full Text] [Related]
54. Attitude towards adherence in patients with schizophrenia at discharge.
Schennach-Wolff R; Jäger M; Seemüller F; Obermeier M; Messer T; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Maier W; Lemke MR; Rüther E; Klingberg S; Gastpar M; Möller HJ; Riedel M
J Psychiatr Res; 2009 Dec; 43(16):1294-301. PubMed ID: 19505697
[TBL] [Abstract][Full Text] [Related]
55. [Treatment adherence in schizophrenia. A comparison between patient's, relative's and psychiatrist's opinions].
Giner J; Cañas F; Olivares JM; Rodriguez A; Burón JA; Rodríguez-Morales A; Roca M
Actas Esp Psiquiatr; 2006; 34(6):386-92. PubMed ID: 17117335
[TBL] [Abstract][Full Text] [Related]
56. Sociodemographic and clinical factors associated with relapse in schizophrenia.
Chabungbam G; Avasthi A; Sharan P
Psychiatry Clin Neurosci; 2007 Dec; 61(6):587-93. PubMed ID: 18081617
[TBL] [Abstract][Full Text] [Related]
57. Enhancing medication adherence in people with schizophrenia: an international programme of research.
Gray R; White J; Schulz M; Abderhalden C
Int J Ment Health Nurs; 2010 Feb; 19(1):36-44. PubMed ID: 20074202
[TBL] [Abstract][Full Text] [Related]
58. [Therapeutic benefit of a registered psychoeducation program on treatment adherence, objective and subjective quality of life: French pilot study for schizophrenia].
Sauvanaud F; Kebir O; Vlasie M; Doste V; Amado I; Krebs MO
Encephale; 2017 May; 43(3):235-240. PubMed ID: 27658989
[TBL] [Abstract][Full Text] [Related]
59. Understanding adherence to neuroleptic treatment in schizophreniaí.
Vauth R; Löschmann C; Rüsch N; Corrigan PW
Psychiatry Res; 2004 Apr; 126(1):43-9. PubMed ID: 15081626
[TBL] [Abstract][Full Text] [Related]
60. Sertindole for the treatment of schizophrenia.
Azorin JM; Kaladjian A; Fakra E; Adida M
Expert Opin Pharmacother; 2010 Dec; 11(18):3053-64. PubMed ID: 21080854
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
